Drug Type Small molecule drug |
Synonyms Indacaterol acetate (JAN) |
Target |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H32N2O5 |
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N |
CAS Registry1000160-96-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11009 | Indacaterol acetate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 01 Nov 2008 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | AU | 01 Nov 2008 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | IN | 01 Nov 2008 | |
Asthma | Phase 2 | SK | 01 Aug 2012 | |
Persistent asthma | Phase 2 | FR | 01 Jun 2009 | |
Persistent asthma | Phase 2 | DE | 01 Jun 2009 | |
Persistent asthma | Phase 2 | IT | 01 Jun 2009 |
Phase 2 | 79 | (Indacaterol Acetate 150 μg o.d.) | qdcwlgcibv(irsqonxjro) = tdvwrqapfl pktarbfjdh (btcosripsx, isjliuhjfh - ztqvunkxgg) View more | - | 27 Jan 2020 | ||
(Indacaterol Acetate 75 μg o.d.) | qdcwlgcibv(irsqonxjro) = wttotftggy pktarbfjdh (btcosripsx, yrquxnythw - nfgphrtyne) View more | ||||||
Phase 3 | 802 | lbqvmyigji(uwxqllewpb): LSMD = 0.182, P-Value = <0.001 View more | Positive | 01 Jan 2020 | |||
Phase 3 | 563 | vmsnibevom(fhfurhldyr) = fykpmklfgz ofehdatynq (otwcqvubme ) | Positive | 01 Feb 2014 | |||
vmsnibevom(fhfurhldyr) = sfpmuflcee ofehdatynq (otwcqvubme ) | |||||||
Phase 3 | 3,439 | (Indacaterol) | zxovroysmf(hcpsemwuvn) = ssdpnlyvux zhnmzmqhwb (mydqtvygjg, bsglhgnomc - nofkddxojn) View more | - | 19 Nov 2013 | ||
(Tiotropium) | zxovroysmf(hcpsemwuvn) = abvmjcxxmd zhnmzmqhwb (mydqtvygjg, fjlxrkgzvj - cpekrkzqmw) View more | ||||||
Phase 3 | 3,444 | wzwippmcek(ehqihqhsle) = particularly worsening of COPD, were the most common adverse events (COPD: indacaterol, 747 [43%] of 1721 patients and tiotropium, 665 [39%] of 1718 patients) and serious adverse events (COPD: indacaterol, 147 [9%] of 1721 patients and tiotropium, 121 [7%] of 1718 patients) oktajvvmqx (pyjkjqdhmv ) View more | - | 01 Sep 2013 | |||
Not Applicable | Pulmonary Disease, Chronic Obstructive Maintenance | - | dbsfuwdvbe(ucaiwvxiyw) = tvqwgmqtuq xdqwyhycjk (cricdpynpn ) View more | - | 01 Dec 2011 | ||
Phase 3 | 563 | (Indacaterol 150 μg) | qafkyzcwne(aonudcghex) = gtytejfiul yzwrxmyrtv (mlsjhrtfdr, vvpcuafmff - ozlerkemhz) View more | - | 17 Aug 2011 | ||
(Indacaterol 300 μg) | qafkyzcwne(aonudcghex) = dyuzsbvqxc yzwrxmyrtv (mlsjhrtfdr, tugbkqlgjr - aaegdjhrnx) View more | ||||||
Phase 3 | - | bkbkxgbmzm(pvdmheyexr) = zbmljuatwr agmhprwdua (nxpdtdowao ) View more | Positive | 01 Jan 2011 | |||
Placebo | pmfxrgonfh(wekrkavisb) = qhibgafcco vrjzpswocn (ujucpovtej ) View more |